Literature DB >> 9603976

Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.

B Canard1, S R Sarfati, C C Richardson.   

Abstract

Human immunodeficiency virus type 1 is resistant to 3'-azido-3'-deoxythymidine (AZT) when four amino acid substitutions (D67N, K70R, T215F, and K219Q) are present simultaneously in its reverse transcriptase. Wild-type and AZT-resistant reverse transcriptases show identical binding to a 3'-azido-3'-deoxythymidine 5'-monophosphate (AZTMP)-terminated primer/RNA template. On DNA templates, the equilibrium dissociation constant (KD) for primer/template and AZT-resistant reverse transcriptase (RT) (KD = 4.1 nM) is similar to that of the wild-type enzyme (KD = 6.2 nM). However, koff is 4-25-fold lower for the AZT-resistant enzyme than for the wild-type enzyme, depending on the nucleotide and the template. The kinetic decay of a wild-type RT/primer/AZTMP-terminated DNA template complex is biphasic. Seventy percent of the initial complex decays with a rate constant greater than 0.05 s-1, and 30% with a rate constant of 0.0017 s-1. Decay of an AZT-resistant RT/AZTMP-terminated primer/DNA template complex is monophasic, with a rate constant of 0.0018 s-1. The last two nucleotides at the 3' end of the AZTMP-terminated DNA primer in complex with AZT-resistant RT, but not wild-type RT, and a DNA template are protected from exonuclease digestion, suggesting that enhanced binding of the 3' end of the AZTMP-terminated DNA primer to reverse transcriptase is involved in the mechanism of AZT resistance by human immunodeficiency virus type 1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603976     DOI: 10.1074/jbc.273.23.14596

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  The glutamine side chain at position 91 on the β5a-β5b loop of human immunodeficiency virus type 1 reverse transcriptase is required for stabilizing the dNTP binding pocket.

Authors:  Nootan Pandey; Chaturbhuj A Mishra; Dinesh Manvar; Alok K Upadhyay; Tanaji T Talele; Thomas W Comollo; Neerja Kaushik-Basu; Virendra N Pandey
Journal:  Biochemistry       Date:  2011-08-23       Impact factor: 3.162

2.  Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.

Authors:  N Richard; H Salomon; R Rando; T Mansour; T L Bowlin; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.

Authors:  H Sato; Y Tomita; K Shibamura; T Shiino; T Miyakuni; Y Takebe
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Structural basis for activation of alpha-boranophosphate nucleotide analogues targeting drug-resistant reverse transcriptase.

Authors:  P Meyer; B Schneider; S Sarfati; D Deville-Bonne; C Guerreiro; J Boretto; J Janin; M Véron; B Canard
Journal:  EMBO J       Date:  2000-07-17       Impact factor: 11.598

5.  Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Peter R Meyer; Suzanne E Matsuura; Adviye A Tolun; Ingrid Pfeifer; Antero G So; John W Mellors; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.

Authors:  M Götte; D Arion; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.

Authors:  A Mas; M Parera; C Briones; V Soriano; M A Martínez; E Domingo; L Menéndez-Arias
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

8.  Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Peter R Meyer; Suzanne E Matsuura; Dianna Zonarich; Rahul R Chopra; Eric Pendarvis; Holly Z Bazmi; John W Mellors; Walter A Scott
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine.

Authors:  Shannon Zelina; Chih-Wei Sheen; Jessica Radzio; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

10.  Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism.

Authors:  P R Meyer; S E Matsuura; A G So; W A Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.